Resumen

ALVIAREZ, Elena  y  GONZALEZ, María. Efectividad y tolerabilidad de la Citicolina en el Ictus Isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo. AVFT [online]. 2007, vol.26, n.2, pp.127-130. ISSN 0798-0264.

Badground: Previous studies have suggested that the CDP choline reduces the neurological symptoms in patient with cerebral ischemic, accelerating the recovery of the motors symptoms, the conscience and diminishing the volume of the infarct. Objective: To evaluated affectivity of Citicholine in acute Ictus. Methods: It was a prospective, randomized, double blind, of parallel groups study. A group received conventional treatment plus citicholine 1000 mg endovenous each 12 h. for 3 days, after 2g VO, for 6 weeks, and other placebo. Were evaluated: NIHSS, BARTHEL, RANKIN and volume of the infarct. The evaluations were carried out at 3 and 6 weeks. Results: The study was carried out in 77 patients, 65 patients entered to analysis. BARTHEL: Point of court of 50 points. After the treatment, the group that received citicholine, 55 % were independent and in placebo group 43.3% were independent (P: 0.52). RANKIN: The court point is smaller than 3. At the end of the treatment had a score smaller than 3, 33.3% patient placebo group and 45% in the Citicoline group (P 0.002). The final volume was inferior in the Citicholine group (P 0.057). Tolerance: A patient in the active group with antecedent of gastric ulcer, bled, adverse effects were not reported in the group placebo. Conclusions: The Citicholine was superior to placebo to improve the percentage of patients that can be assisted to if same after an episode of ictus acute, taken place by the occlusion of the cerebral media artery.

Palabras clave : Barthel; Citicholine; ICC; Ictus; NIHSS; Rankin.

        · resumen en Español     · texto en Español     · Español ( pdf )